Electrophysiology: Parts 1 and 2
Thursday, December 3rd: 1:30 – 3:30 pm and 4:00 – 5:30 pm
I know what you are thinking. Electrophysiology is old, and boring, and you already know everything you need to know. WRONG. In this 2 part session, we will change your mind, and bring you up-to-date on the past, present, and future of electrophysiology. In fact, Part 1 is called, “Old Therapies, New Twists, and Science Gaps in Electrophysiology: What Do We Do Next?”
This first session is chaired by Prof. Gerhard Hindricks from the University of Leipzig in Leipzig, Germany where he leads one of the largest EP departments in Europe, and Dr. Elaine Hylek, from the Clinical & Translational Science Institute (CTSI) at the Boston University School of Medicine in Boston, MA, USA.
Come hear the debates on atrial fibrillation trials. Should rhythm control guidelines be updated in light of the results of the EAST trials? What is the role of left atrial appendage closure vs. DOAC therapy? Should we treat device-detected AF or wait for more science? Speakers include: Gerhard Hindricks (Leipzig, GER), Vivek Reddy (New York, USA), and Cecilia Linde (Stockholm, SWE).
What about cardiac implantable electronic devices? Do we always need randomized trials to compare safety and efficacy? What is the evidence for leadless pacing vs. standard transvenous pacing? How do we counsel our patients about totally subcutaneous implantable cardioverter-defibrillator (ICDs) vs. transvenous ICDs? How do we assess the totality of evidence for optimal implementation of electrophysiology therapies? Speakers include Jon Piccini (Durham, USA), Thomas Deering (Atlanta, USA), and Andrea Russo (Camden, USA).
Prepare your questions, and weigh in on the debates during the moderated multi-stakeholder expert panel debate titled “How to Progress From New Evidence to Implementation.” The speakers will be joined by additional trialists, as well as members of industry and regulatory agencies who will provide their unique points of view.
Part 2 of the electrophysiology session focuses on the impact of the digital world on research and clinical implementation of electrophysiology therapies. This session, titled, “Digital Health to Jumpstart a New Era in Electrophysiology” will be chaired by Prof. Cecilia Linde from the Theme of Heart and Vessels at the Karolinska University Hospital Stockholm, Sweden and Dr. Andrea Russo from the Cooper Medical School of Rowan University in Camden, NJ, USA. Both cardiologists are expert researchers in the area of implantable devices for heart failure management.
This session will take an in depth look at strategies to improve electrophysiology trials by making electronic monitoring modalities the routine standard of practice (David McManus, Worcester, USA), and integrating new approaches and technologies. But the big question we all ask is how do we ensure patients reap the benefits seen in clinical trials? Well come hear Dr. Jonathan Piccini (Durham, USA) present strategies to enhance the adoption of new techniques into clinical practice.
Dr. Rob Kowal (VP and CMO of the Cardiac Rhythm and Heart Failure Division at Medtronic, USA) and Dr. Kenneth Stein (SVP and CMO for Rhythm Management and Global Health Policy at Boston Scientific, USA) will provide industry perspectives, Dr. George Van Hare (US FDA) and Dr. Giuseppe Rosano (EMA) will provide a regulatory viewpoints. Not to be missed, and not often heard, at most scientific meetings, are the perspectives of Payers (Steven Farmer, CMS, USA) and patients (Melanie True Hills, American Foundation for Women’s Health, USA).